Accuray Shares Plunged: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Accuray (Nasdaq: ARAY  ) dropped 13% in intraday trading today after announcing disappointing third-fiscal-quarter earnings.

So what: Q3 non-GAAP earnings per share of $0.02 fell short of the consensus estimate of $0.04. Operating expenses -- sales and marketing, R&D, and general and administrative -- increased more than revenue, primarily because of $2.6 million in expenses related to a planned acquisition. Revenue grew 5% year over year.

Now what: Management noted that the backlog grew 18% year over year and reiterated fiscal 2011 revenue guidance of $210 million to $225 million. That points to revenue growth of 5% to 29% in the current (fourth fiscal) quarter. Management expects that its deal to acquire TomoTherapy will close in June or July and be accretive to fiscal 2012 earnings. It will take a lot of accretion to justify the company's uneven financial performance and its P/E ratio of 99.  

Interested in more info on Accuray? Add it to My Watchlist.

Fool contributor Cindy Johnson owns no shares of any company named above. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 06, 2011, at 9:49 PM, jorgecorrear wrote:

    ARAY is a good company with a bright future, this drop is a tipical move of short sellers and false rumors from people who are betting to scare people who do not know well the product ARAY is selling worldwide.

    This innovative company, like TOMO and VAR will see soon betters days, and I won't be surprised if is picked by Fool's experts.

    ARAY has a glowing future in medical devices.

    Long on ARAY since 6$ and up, buying more on dips like today 5/6/2011. Target 3-5 years 50$.

    Maybe take-over target by partner Siemens A.G.

Add your comment.

DocumentId: 1490551, ~/Articles/ArticleHandler.aspx, 4/17/2014 11:34:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement